Indian Immunologicals Limited Introduces India’s First Indigenous Hepatitis A Vaccine for Children
Hyderabad-based Indian Immunologicals Limited (IIL) has launched Havisure (0.5 ml), the first-ever made-in-India Hepatitis A vaccine for children. This groundbreaking development marks a crucial step forward in the country’s healthcare sector, offering an affordable solution to protect children from the contagious liver disease caused by the Hepatitis A virus (HAV). The vaccine is part of IIL’s ongoing efforts to improve public health and provide cost-effective vaccines to vulnerable populations, especially children.
Tackling Hepatitis A
Hepatitis A is a highly contagious liver infection that primarily affects children and can lead to serious health issues. Vaccination remains the most efficient and cost-effective method of preventing this disease. The introduction of Havisure not only provides an essential protective measure for children but also reinforces IIL’s commitment to enhancing the health and well-being of the country’s youth.
IIL’s Commitment to Innovation and Public Health
Dr. K. Anand Kumar, Managing Director of Indian Immunologicals Limited, expressed his enthusiasm for the launch, stating, “We are thrilled to introduce Havisure, India’s first indigenously developed Hepatitis A vaccine for children. As the largest contributor to vaccine self-sufficiency in India, this launch demonstrates our relentless focus on innovation and public health.”
Dr. Kumar also highlighted the vaccine’s role in supporting the “Make in India” initiative, noting that this launch serves as a testament to IIL’s dedication to developing indigenous solutions for public health. “We believe this vaccine will contribute to a healthier future for the younger generation, particularly as we celebrate Teachers’ Day—a day symbolic of nurturing and shaping the future,” he added.
A Breakthrough in Vaccine Development
The launch of Havisure solidifies IIL’s position as the only company in India to develop an indigenous Hepatitis A vaccine, with formulations available for both pediatric (0.5 ml) and adult (1 ml) use. This innovation underscores the company’s long-standing dedication to making life-saving vaccines accessible and affordable for all, with a particular focus on children.
As IIL continues to be a key player in India’s self-reliance in vaccine production, the introduction of Havisure is a critical advancement in the country’s ongoing efforts to combat preventable diseases.
For the latest updates on this and other healthcare innovations, visit Newztalkies.com, where this article will be published. Stay connected with Newztalkies.com for comprehensive coverage of public health breakthroughs and developments across India and the world.
By the team at Newztalkies.com.
